SSRIs, the most widely prescribed class of antidepressants, can affect the eyes in ways that range from mild dryness and blurred vision to rarer but more serious problems like optic neuropathy and glaucoma. These effects stem partly from the fact that serotonin receptors are present throughout the eye’s internal structures, meaning a drug designed to change serotonin signaling in the brain inevitably changes it in ocular tissues too. The spectrum of reported eye issues is broader than most prescribing guides suggest, and some of the effects interact with each other in ways that are still being worked out.
Why Serotonin Matters Inside the Eye
Most people associate serotonin with mood, but the eye has its own population of serotonin receptors. Studies using molecular probes have identified serotonin receptor subtypes in the ciliary body, the ciliary epithelium, the trabecular meshwork, and the iris, all of which are structures involved in regulating how fluid moves through the eye and how much pressure builds up inside it.1PubMed. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action Binding studies have confirmed a particularly high density of serotonin-2 receptor sites in the iris, ciliary epithelium, and the longitudinal ciliary muscle.2PubMed. Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension When an SSRI raises serotonin availability body-wide, these receptors get more stimulation than they normally would, and the downstream consequences can show up as changes in pupil size, fluid drainage, and even the health of retinal cells.
Dry Eyes
Dry eye is one of the most common complaints among SSRI users, and it tends to be underappreciated because dryness seems trivial compared to the psychiatric condition being treated. But chronic dryness is genuinely uncomfortable and can degrade vision quality over time. In a study comparing antidepressant users to controls using the Schirmer test, which measures how much tear fluid the eye produces, patients on SSRIs had significantly lower tear production than the control group. Interestingly, SSRI users actually had lower wetting measurements than patients taking SNRIs, and the difference did not depend on how long the person had been on the drug.3PubMed. Dry Eye Related to Commonly Used New Antidepressants
What makes this finding puzzling is that SSRIs, with the exception of paroxetine, are not supposed to have strong anticholinergic effects. Anticholinergic activity is the usual explanation for drug-induced dry eye because it directly interferes with the glands that produce tears. The fact that SSRIs cause dryness anyway suggests something else is going on, possibly a serotonin-mediated effect on tear gland signaling that researchers have not fully mapped out yet. For people already dealing with dry eye from contact lenses, screen time, or autoimmune conditions, adding an SSRI can make the problem noticeably worse.
Blurred Vision and the Spectrum of Visual Complaints
Blurred vision is the single most frequently reported eye-related side effect of SSRIs. A review of patient-reported visual problems linked to serotonin reuptake inhibitors found that about two-thirds of reports involved blurred vision or reduced visual acuity. Other commonly reported symptoms included night blindness (roughly 18%), floaters (about 17%), light sensitivity (about 15%), and double vision (around 12%).4PubMed. Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants That study also highlighted a troubling pattern: 49 patients reported enduring vision problems even after they stopped taking the medication, which suggests that some of these effects are not simply reversible on discontinuation.
A separate analysis of FDA adverse event reports confirmed that SSRIs as a class are significantly associated with eye disorders, and found that most of these adverse events showed up within the first 30 days of treatment. The reported incidence of severe eye disorders was roughly 39% for SSRIs overall, with fluoxetine exhibiting the highest rate at about 46%.5PubMed. Eye disorders associated with selective serotonin reuptake inhibitors: a real-world disproportionality analysis of FDA adverse event reporting system These numbers come from spontaneous adverse event reports, so they reflect the severity of the cases that actually get reported rather than the overall rate among all SSRI users. Still, the fact that nearly half of fluoxetine-related eye reports were classified as severe is worth paying attention to.
Pupil Dilation and the Risk of Angle-Closure Glaucoma
SSRIs can cause mydriasis, a sustained widening of the pupil. This happens partly through serotonin’s effect on iris muscles, but research on fluoxetine specifically suggests the mechanism is more complicated than pure serotonin reuptake inhibition. Studies on photosensitive retinal ganglion cells found that fluoxetine suppresses their light responses in a way that citalopram, a more selective SSRI, does not replicate. That points to off-target effects on other neurotransmitter systems, including dopamine and ion channels called TREK-1, rather than serotonin alone.6Investigative Ophthalmology and Visual Science. Inhibitory effects of fluoxetine on photosensitive retinal ganglion cells
Mydriasis matters most for people with narrow drainage angles in their eyes. When the pupil dilates, the iris bunches up and can physically block the trabecular meshwork, which is the tissue that drains fluid out of the eye. If the drainage angle is already anatomically narrow, this blockage can trigger a sudden, painful spike in eye pressure known as acute angle-closure glaucoma. A large population-based study in Taiwan found that SSRI users had a modestly increased risk of glaucoma, with an adjusted odds ratio of about 1.09 across all users. But the risk was considerably higher in people who used SSRIs for over a year or at higher doses, where the adjusted odds ratio climbed to around 1.36.7PubMed Central. Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study
Genetic variation in the liver enzyme CYP2D6, which metabolizes several SSRIs, can affect how much active drug reaches the eye. People who metabolize these drugs slowly end up with higher blood levels for longer, potentially amplifying ocular side effects. Combining an SSRI with other medications that also cause mydriasis or that inhibit CYP2D6 can further increase the risk of angle closure.8Survey of Ophthalmology. Association between serotonin-norepinephrine reuptake inhibitors and acute angle closure: What is known? If you have been told you have narrow angles, or if angle-closure glaucoma runs in your family, this is something to flag with both your prescriber and your eye doctor before starting an SSRI.
The Intraocular Pressure Paradox
The relationship between SSRIs and eye pressure is not straightforward, and it sometimes confuses both patients and clinicians. In people with normal, open drainage angles, SSRIs tend to lower intraocular pressure. One study found that patients on SSRIs had significantly lower eye pressure than controls, regardless of whether they had been on the medication for less than or more than six months.9PubMed. Effects of selective serotonin reuptake inhibitors on intraocular pressure and anterior segment parameters in open angle eyes A small clinical study of a single dose of fluoxetine, however, showed a short-term increase in pressure, even if the increase was not symptomatic.10PubMed. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms
So the picture looks different depending on the anatomy of the individual eye and the time frame you are looking at. For the majority of SSRI users whose eyes have normal drainage, the long-term effect is a mild reduction in pressure, which is unlikely to cause problems and could theoretically even be mildly protective. For the minority with narrow angles, however, the same drug can trigger the opposite outcome. This is why a blanket statement like “SSRIs raise eye pressure” or “SSRIs lower eye pressure” misses the point. Both can be true in different people.
Optic Neuropathy
Optic neuropathy, damage to the optic nerve that carries visual information from the eye to the brain, is one of the more alarming potential complications of SSRI use, though it appears to be uncommon. A case series published in the journal Eye documented patients who developed confirmed optic neuropathy while on SSRIs, with a vascular origin suspected in all cases. Causality scoring using the Naranjo scale rated the adverse drug reaction as probable in one case and possible in the remaining four. In some patients, stopping the SSRI appeared to help protect the unaffected eye, and partial recovery of vision was observed.11Eye. SSRI-associated optic neuropathy
The suspected mechanism involves vasoconstriction of the small blood vessels that feed the optic nerve head. Serotonin is a vasoactive molecule; when its levels rise, blood vessels in certain tissues can constrict. If the tiny arteries supplying the optic nerve get squeezed enough, the nerve tissue loses blood flow and can be damaged, a process similar to what happens in non-arteritic anterior ischemic optic neuropathy. This is particularly concerning for people who already have vascular risk factors like diabetes, high blood pressure, or sleep apnea. The evidence here comes from case reports and small series rather than large trials, which means the true incidence is unknown, but it also means the condition may be underrecognized.
Retinal Thinning and Maculopathy
Beyond the optic nerve, SSRIs may affect the retina itself. A study using optical coherence tomography, the imaging tool eye doctors use to measure retinal layers, found that SSRI users had significantly thinner foveal tissue compared to controls. They also showed reduced ganglion cell complex thickness in specific quadrants around the macula.12PubMed. Effects of Selective Serotonin Reuptake Inhibitors on Macular Ganglion Cell Complex Thickness and Peripapillary Retinal Nerve Fiber Layer Thickness These are subtle structural changes, and it is not yet clear whether they progress to functional vision loss in most people, but they suggest that prolonged serotonin modulation is doing something measurable to retinal cells.
Sertraline in particular has been linked to maculopathy. A case series identified several patients who developed disruption of the outer retinal layers and retinal pigment epithelium while on sertraline, showing a phenotypically similar pattern across patients on imaging.13PubMed Central. Presumed Sertraline-Associated Maculopathy: A Case Series An earlier case report described a 23-year-old man who rapidly developed bilateral maculopathy with visual blurring shortly after starting sertraline; his symptoms mildly improved after the drug was stopped.14PubMed. Bilateral maculopathy associated with sertraline These cases are rare enough that you should not panic about your retinas if you take sertraline, but they are also specific enough in their pattern to warrant further investigation.
Cataract Risk
Long-term SSRI use appears to modestly increase the likelihood of eventually needing cataract surgery. A large population-based case-control study found that using an SSRI for a year or longer was associated with a roughly 36% increased risk of cataract surgery, with similar numbers in both men and women. Among individual SSRIs, citalopram carried the highest risk, with an odds ratio of about 1.53.15PubMed Central. Selective Serotonin Reuptake Inhibitor Use and Increased Risk of Cataract Surgery: A Population-Based, Case-Control Study
A systematic review and meta-analysis that pooled data from multiple studies arrived at a somewhat more conservative estimate, putting the combined odds ratio for cataract among SSRI users at about 1.12.16PubMed Central. Antidepressants use and risk of cataract development: a systematic review and meta-analysis The gap between the individual study and the meta-analysis likely reflects differences in methodology and the populations included, but both point in the same direction: a real but modest increase. For context, a 12% relative increase in cataract risk is small for any one person, especially since cataracts are extremely common with aging regardless. But for someone already at higher baseline risk, such as a person with diabetes, heavy UV exposure, or prolonged corticosteroid use, the additional contribution from an SSRI is worth knowing about.
The proposed mechanism involves serotonin’s effect on the lens. Serotonin receptors are present on lens epithelial cells, and sustained serotonergic stimulation may promote oxidative stress or alter the transport of ions and fluid across the lens, both of which can accelerate the clouding process. Exposure to UV light while on an SSRI could theoretically compound this effect, though that interaction has not been tested rigorously.
Visual Snow and Persistent Visual Disturbances
One of the more unsettling possible consequences of SSRI use is the development of visual snow, a condition where a person sees constant static or flickering dots across their visual field, similar to television noise. A review of reported cases found 24 people who developed visual snow after starting a serotonin reuptake inhibitor, with a mean age of 30. Nearly all of them (92%) had stopped the suspect drug by the time of reporting, but their symptoms had not resolved.17PubMed Central. Serotonin reuptake inhibiting antidepressants: A trigger for visual snow syndrome? That persistence is what makes visual snow particularly concerning: unlike blurred vision or dry eye, which usually improve after stopping the medication, visual snow can become a permanent feature of someone’s visual experience.
Visual snow is not the same as the transient visual disturbances that many SSRI users experience in the first weeks of treatment. Palinopsia, the afterimage phenomenon where you see traces or ghosts of objects after looking away, was reported by about 10% of patients in one series of SSRI-related visual complaints. Photopsia, seeing flashes of light, appeared at a similar rate.4PubMed. Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants These symptoms are thought to arise from changes in cortical visual processing rather than from structural damage to the eye itself, which is why standard eye exams often come back normal in people who report them. That can be frustrating for patients who feel dismissed when their ophthalmologist finds nothing wrong.
Which SSRIs Carry the Highest Eye Risk
Not all SSRIs are equal when it comes to ocular side effects. The FDA adverse event analysis found distinct patterns: escitalopram was most strongly associated with blurred vision, citalopram with angle-closure glaucoma, and paroxetine with photopsia.5PubMed. Eye disorders associated with selective serotonin reuptake inhibitors: a real-world disproportionality analysis of FDA adverse event reporting system Fluoxetine stood out for having the highest rate of severe eye-related adverse events. Sertraline has the strongest association with maculopathy based on case reports. The cataract data point to citalopram as carrying the most risk on that front.15PubMed Central. Selective Serotonin Reuptake Inhibitor Use and Increased Risk of Cataract Surgery: A Population-Based, Case-Control Study
These drug-specific differences probably reflect varying degrees of affinity for serotonin receptor subtypes, differing anticholinergic activity (paroxetine is the most anticholinergic SSRI), and differences in how each drug interacts with non-serotonergic systems like dopamine reuptake or ion channels. The practical takeaway: if you develop an eye symptom on one SSRI, switching to a different one is a reasonable discussion to have with your prescriber, since the side-effect profiles genuinely differ.
Serotonin Syndrome and the Eyes
Serotonin syndrome is a potentially dangerous condition that occurs when serotonin activity becomes excessive, typically from drug combinations rather than a single SSRI alone. The eyes can provide early warning signs. Mydriasis is one of the recognized physical findings, and a prospective observational study of 45 patients with serotonin syndrome documented ocular clonus, a distinctive rhythmic bouncing movement of the eyes, as one of the clinical signs.18PubMed Central. Refining the Clinical Features of Serotonin Syndrome: A Prospective Observational Study of 45 Patients If you are on an SSRI and develop new-onset dilated pupils combined with agitation, rapid heart rate, tremor, or muscle jerking, that combination of symptoms warrants urgent medical evaluation. The eye findings alone are not diagnostic, but in context they can help clinicians identify the syndrome faster.
How Depression Itself Affects Vision
One of the complications in studying SSRI eye effects is that depression itself appears to alter visual processing. Research using pattern electroretinography found that patients with active depression had significantly reduced retinal contrast processing compared to healthy controls. When those patients went into remission with antidepressant treatment, their retinal contrast response returned to normal levels. Patients who did not achieve remission continued to show the same deficit.19The British Journal of Psychiatry. Effect of antidepressive therapy on retinal contrast processing in depressive disorder A preliminary study on escitalopram specifically found that treatment led to measurable changes in macular function as assessed by electrophysiology.20Klinika Oczna / Acta Ophthalmologica Polonica. The influence of escitalopram therapy on macular function in patients with major depression – preliminary report
This creates a genuinely tricky situation for patients and clinicians. Some of the visual symptoms a person notices when starting an SSRI, particularly reduced contrast sensitivity or the sense that colors look washed out, may have been caused by the depression rather than the drug. And some improvements in vision during treatment may reflect the lifting of depression rather than a direct ocular benefit of the medication. Disentangling the drug’s effects from the disease’s effects on vision is an active area of research, and it is one reason why blanket claims about SSRIs and vision need to be treated with some caution in both directions.
Practical Steps if You Notice Eye Changes on an SSRI
If you develop new visual symptoms while taking an SSRI, the first step is to not dismiss them as “just stress” or “just the depression.” Blurred vision, increased light sensitivity, and dry eyes are common enough on SSRIs that they deserve at least a conversation with your prescriber. Acute symptoms like sudden eye pain, halos around lights, nausea, and a rock-hard feeling eyeball are potential signs of angle-closure glaucoma and require emergency attention.
For less urgent symptoms, a baseline eye exam before starting an SSRI is a reasonable precaution, especially if you have a family history of glaucoma or already have dry eye disease. People with narrow angles can be identified with a simple examination, and if your angles are narrow, your ophthalmologist can perform a preventive laser procedure that essentially eliminates the angle-closure risk. That procedure takes a few minutes and is widely available, so having narrow angles is not a reason to avoid SSRIs entirely; it is just a reason to get checked first. If you are on a long-term SSRI and have never had an eye exam, it is worth scheduling one to get a structural baseline you can compare against later.